A Phase I and Pharmacokinetic Study of SR-45023A Administered Once Every 7 Days
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2018
At a glance
- Drugs SR 45023A (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 27 Sep 2005 New trial record.